Feb 7 (Reuters) – Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill. (Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Continues to keep Dynamic Currency Conversion (DCC) charges at Zero Mumbai (Maharashtra) [India], August 13:…
Mumbai (Maharashtra) [India], August 13: From unexplained career setbacks to emotional turmoil, celebrity astrologer Saurish…
By Lisa Richwine LOS ANGELES, Aug 13 (Reuters) - Singer and actor Selena Gomez was…
Left to right: Dr. Mannan Akhtar, DDA Commissioner (Lands); Shri N. Saravana Kumar, Vice Chairman,…
BENGALURU, Aug 14 (Reuters) - An Indian appeals tribunal granted Zee Entertainment partial relief from…
Bengaluru (Karnataka) [India], August 14: The Rajiv Gandhi Institute of Petroleum Technology (RGIPT), Bengaluru Campus,…